Neoadjuvant capecitabine plus docetaxel ± trastuzumab therapy for recently diagnosed breast cancer:: phase II results

被引：0
|
作者：
Tripathy, D.
Moisa, C.
Gluck, S.
机构：
[1] Univ Texas SW Med Ctr, Dallas, TX USA
[2] Roche Labs Inc, Nutley, NJ USA
[3] Univ Miami, Miami, FL 33152 USA
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2007年 / 106卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S226 / S226
页数：1
相关论文
共 50 条
  • [1] Trastuzumab plus capecitabine and docetaxel as first-line therapy for metastatic breast cancer: Phase II results
    Gennatas, C. G.
    Michalaki, V.
    Gennatas, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [2] Capecitabine plus docetaxel plus bevacizumab as neoadjuvant therapy for invasive breast cancer: results of a phase II pilot study.
    Greil, R.
    Moik, M.
    Reitsamer, R.
    Ressler, S.
    Stoll, M.
    Namberger, K.
    Menzel, C.
    Mlineritsch, B.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S188 - S188
  • [3] Docetaxel (T) plus capecitabine (X) with or without trastuzumab (H) neoadjuvant therapy for locally advanced breast cancer (BC): Phase II study
    Lybaert, W.
    Wildiers, H.
    Neven, P.
    Amant, F.
    Christiaens, M.
    Van Limbergen, E.
    Weltens, C.
    Drijkoningen, R.
    Debrock, G.
    Paridaens, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [4] Safety and efficacy of the combination of trastuzumab plus capecitabine and docetaxel as first-line therapy for metastatic breast cancer: phase II results
    Michalaki, V.
    Gennatas, S.
    Gennatas, C.
    EJC SUPPLEMENTS, 2009, 7 (02): : 276 - 276
  • [5] Trastuzumab plus Capecitabine and Docetaxel as First-line Therapy for HER2-positive Metastatic Breast Cancer: Phase II Results
    Michalaki, Vasiliki
    Fotiou, Stylianos
    Gennatas, Spyridon
    Gennatas, Constantine
    ANTICANCER RESEARCH, 2010, 30 (07) : 3051 - 3054
  • [6] A phase II trial of Neoadjuvant docetaxel and capecitabine for locally advanced breast cancer
    Lebowitz, PF
    Eng-Wong, J
    Swain, SM
    Berman, A
    Merino, MJ
    Chow, CK
    Venzon, D
    Zia, F
    Danforth, D
    Liu, E
    Zujewski, J
    CLINICAL CANCER RESEARCH, 2004, 10 (20) : 6764 - 6769
  • [7] Randomized Phase II Trial of First-Line Trastuzumab Plus Docetaxel and Capecitabine Compared With Trastuzumab Plus Docetaxel in HER2-Positive Metastatic Breast Cancer
    Wardley, Andrew M.
    Pivot, Xavier
    Morales-Vasquez, Flavia
    Zetina, Luis M.
    Dias Gaui, Maria de Fatima
    Reyes, Douglas Otero
    Jassem, Jacek
    Barton, Claire
    Button, Peter
    Hersberger, Veronica
    Torres, Antonio Anton
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (06) : 976 - 983
  • [8] Low-dose capecitabine plus docetaxel as first-line therapy for metastatic breast cancer: phase II results
    Michalaki, Vasiliki
    Gennatas, Spyridon
    Gennatas, Konstantine
    ANTI-CANCER DRUGS, 2009, 20 (03) : 204 - 207
  • [9] A Randomized Phase II Trial of Capecitabine Plus Vinorelbine Followed by Docetaxel Versus Adriamycin Plus Cyclophosphamide Followed by Docetaxel as Neoadjuvant Chemotherapy for Breast Cancer
    Yoo, Changhoon
    Kim, Sung-Bae
    Ahn, Jin-Hee
    Kim, Jeong Eun
    Jung, Kyung Hae
    Gong, Gyung-Yub
    Son, Byung-Ho
    Ahn, Sei-Hyun
    Ahn, Seung Do
    Kim, Hak-Hee
    Shin, Hee Jung
    Kim, Woo Kun
    CANCER RESEARCH AND TREATMENT, 2015, 47 (03): : 406 - 415
  • [10] A phase II trial of docetaxel plus carboplatin plus bevacizumab as neoadjuvant therapy for triple negative breast cancer
    Chacon Lopez-Muniz, J. I.
    Cardenas, J. D.
    Santos Rodriguez, A. K.
    Esteban Esteban, M. C.
    Munoz Platon, E.
    Rubio Salvador, A. R.
    Alonso Soler, S. E.
    Fernandez Franco, L.
    San Juan del Moral, A.
    Burgueno Lorenzo, I.
    Trujillo Alba, B. L.
    Martinez Moreno, E.
    Moya Gomez, P.
    Cruz Mora, M. A.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S283 - S283
12345